Tesi Raymond Joseph
Known title: President and CEOCIK: 0001767280
Tesi Raymond Joseph's purchase track record
Tesi Raymond Joseph has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/12/2024 | INMB | $98K | -23.8% | +25.8% | -1.3% |
| 5/26/2022 | INMB | $40K | +40.9% | +11.5% | -0.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| INMB | ▲ Buy | Open Market | 15,380 | $98K | 9/12/2024 | View on chart |
| INMB | ▲ Buy | Grant | 18,028 | $150K | 4/19/2024 | View on chart |
| INMB | ▲ Buy | Open Market | 6,300 | $40K | 5/26/2022 | View on chart |
| INMB | ▲ Buy | Grant | 23,724 | $200K | 3/22/2022 | View on chart |
| INMB | ▼ Sell | Open Market | 3,626 | $73K | 11/3/2021 | View on chart |
| INMB | ▼ Sell | Open Market | 6,517 | $130K | 10/27/2021 | View on chart |
| INMB | ▼ Sell | Open Market | 23,616 | $472K | 10/22/2021 | View on chart |
| INMB | ▲ Buy | Option Exercise | 30,000 | $117K | 8/25/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
INmune Bio Announces Attendance at 2026 Maxim Growth Summit
INmune Bio said it will attend the 2026 Maxim Growth Summit. The event is a platform for biotech companies to meet investors and partners. Attendance may raise the company’s profile and open new collaboration opportunities. The stock is currently trading near the lower end of its 52‑week range.
INmune Bio Announces Attendance at 2026 Maxim Growth Summit. INmune Bio said it will attend the 2026 Maxim Growth Summit. The event is a platform for biotech companies to meet investors and partners. Attendance may raise the company’s profile and open new collaboration opportunities. The stock is currently trading near the lower end of its 52‑week range.